Investigation of glutathione S-transferase zeta and the development of sporadic breast cancer by Smith, Robert A et al.
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
r
e
s
e
a
r
c
h
 
a
r
t
i
c
l
e
Research article
Investigation of glutathione S-transferase zeta and the
development of sporadic breast cancer
Robert A Smith*, Joanne E Curran*, Stephen R Weinstein† and Lyn R Griffiths*
*Genomics Research Centre, Griffith University Gold Coast, Southport, Queensland, Australia
†Department of Pathology, Gold Coast Hospital, Southport, Queensland, Australia
Correspondence: A/Prof. Lyn Griffiths, Genomics Research Centre, School of Health Science, Griffith University Gold Coast, PMB 50 Gold Coast
Mail Centre, Southport, QLD 9726, Australia. Tel: +61 7 5552 8664; fax: +61 7 5552 8908; e-mail: L.Griffiths@mailbox.gu.edu.au
Introduction
Breast cancer is the most common malignancy in women
in the Western world, with an incidence approaching one
in 10 in the USA in 1980 [1] and one in 11 in Australia in
1991 [2]. Several genetic and environmental risk factors
for the development of breast cancer are already known,
including mutations within the BRCA1 and BRCA2 genes
[3]. Other risk factors include a maternal relative with
breast cancer, longer reproductive span, obesity, repro-
ductive history and previous breast cancers [2].
Carcinogens in the body are detoxified by specific
enzymes that aid in interception and removal from the cell
or in modification involving addition of chemical residues
to the reactive sites that cause DNA damage, allowing
safe storage, prior to removal [4]. Among these enzymes
are the glutathione S-transferase (GST) superfamily of
enzymes, which prevent the action of electrophilic and
alkylating carcinogens by binding to glutathione [5].
Several GST class enzymes have been studied to deter-
mine their role in breast cancer susceptibility. The GSTM1
null genotype has been variously reported as showing sig-
nificant association in some studies [6] and no association
with breast cancer [2] in other studies. The GSTT1 null
genotype, however, has not been found to be involved in
predisposition to sporadic breast cancer, although there is
evidence that it may play a role in other cancers [2].
GSTP1 has a polymorphism resulting in an amino acid
change from isoleucine to valine, which may predispose to
certain cancers, including breast cancer, and has variously
bp = base pairs; GST = glutathione S-transferase; GSTZ1 = glutathione S-transferase zeta 1; PCR = polymerase chain reaction.
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Abstract
Background: Certain genes from the glutathione S-transferase superfamily have been associated with
several cancer types. It was the objective of this study to determine whether alleles of the glutathione
S-transferase zeta 1 (GSTZ1) gene are associated with the development of sporadic breast cancer.
Methods: DNA samples obtained from a Caucasian population affected by breast cancer and a
control population, matched for age and ethnicity, were genotyped for a polymorphism of the GSTZ1
gene. After PCR, alleles were identified by restriction enzyme digestion and results analysed by chi-
square and CLUMP analysis.
Results: Chi-squared analysis gave a χ2 value of 4.77 (three degrees of freedom) with P = 0.19, and
CLUMP analysis gave a T1 value of 9.02 with P = 0.45 for genotype frequencies and a T1 value of
4.77 with P = 0.19 for allele frequencies.
Conclusion: Statistical analysis indicates that there is no association of the GSTZ1 variant and hence
the gene does not appear to play a significant role in the development of sporadic breast cancer.
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been found to be significant and not significant in breast
cancer [2,7]. With the results from other GST classes in
mind, it is possible that any new GST class discovered may
have an affect on the development of several different kinds
of cancer; hence the present investigation of GSTZ1.
The GSTZ1 gene has a polymorphism recently reported
by Blackburn et al. [8] that is characterised by base
changes from A to G at nucleotides 94 and 124 of the
coding region of the gene. Hence, GSTZ1 has four alleles,
GSTZ1*A  (A94A124),  GSTZ1*B (A94G124),  GSTZ1*C
(G94G124) and GSTZ1*D (G94A124), for which individ-
uals may be homozygotic or heterozygotic. Blackburn et
al. [8] reported the incidences of the alleles of GSTZ1 as
9% for GSTZ1*A, 28% for GSTZ1*B and 63% for
GSTZ1*C; however, they found no incidence of GSTZ1*D
at all and reported that it was non-existent, most probably
due to its rarity. The base changes from A to G at
nucleotides 94 and 124 lead to amino acid alterations
from lysine to glutamic acid (Lys 32 → Glu) and from argi-
nine to glycine (Arg 42 → Gly), respectively [8]. These
amino acid alterations are known to affect the activities of
the resultant GSTZ1 enzyme for different substrates, par-
ticularly dichloroacetates and fluroacetates, affecting the
efficiency of removal for these substances. To date, the
role of this gene in the development of breast cancer has
not been investigated [9]. The purpose of the present
study is to investigate the role of the GSTZ1 gene in the
development of sporadic breast cancer.
Materials and methods
Subjects
The populations tested comprised 103 female individuals
diagnosed with breast cancer and, as a control popula-
tion, 103 females with no cancer history at all. The
affected and control populations were matched for age
and ethnicity, and have been previously described [2,10].
The average ages of the affected and control populations
were 58 ± 12 and 57.5 ± 11.6 years, respectively. Most of
the samples were recruited through collaboration with the
Pathology Department of the Gold Coast Hospital. Addi-
tional affected samples, as well as the entire control popu-
lation, were obtained through the Genomics Research
Centre of Griffith University.
Genotyping
The  GSTZ1  allele for each individual was amplified by
simple PCR, which produced a DNA fragment 311 bp
long. Details of the primers are displayed in Table 1. Since
the GSTZ1 polymorphisms are characterised by two base
changes from A to G at positions 94 and 124 [8], identifi-
cation of each allele was made using restriction enzyme
digestion using two restriction enzymes, FokI and BsmAI.
Once digested, samples were subjected to electro-
phoresis on an agarose gel and the fragment patterns
analysed. With the base changes for each sample identi-
fied, the polymorphisms possessed by that individual
could be determined, except where the individual pos-
sessed both base changes at both locations. In this case,
an allele-specific PCR was used, which amplified only the
copy of the gene with a G nucleotide at position 124 on
the gene. This PCR product was then digested by BsmA1
to determine which nucleotide was at position 94. The
composition of the second gene could then be deduced
without additional PCR. Genotypes were determined as
AA (308 bp), GG (115, 93 bp) or AG (308, 115, 93 bp)
for the FokI polymorphism, and AA (186, 125 bp), GG
(159, 125, 26 bp) or AG (186, 159, 125, 26 bp) for the
BsmAI polymorphism.
Statistical analysis
To determine whether any significant differences in poly-
morphism frequencies occurred between the case and
control populations, allele and genotype frequencies were
compared using the chi-square method and the Monte
Carlo style CLUMP analysis program [11]. This program is
best suited for analysis of multiallelic polymorphic markers
and has been designed to overcome problems relating to
sparse contingency tables. Power calculations indicated
that the study was expected to have a >85% power to
detect a twofold increase in allele or genotype frequency
in the tested populations.
Results
Genotypes and alleles or GSTZ1 were determined in 103
breast cancer affected individuals and in 103 control indi-
viduals, with the frequencies summarised in Tables 2 and
3. The resulting frequencies resemble those noted by
Blackburn et al. [8], except for the presence of the newly
detected GSTZ1*D allele (the rarest) occurring in 5.6% of
individuals in the sample populations. The frequencies
among the genotypes displayed several small differences
that were not significant and, due to the presence of low
numbers in the frequencies, the genotypes could not be
tested using the chi-square method (CLUMP T1 = 9.02,
P = 0.45). With the frequencies for each allele alone con-
sidered, both chi-square and CLUMP methods were
usable. Again, however, no significant differences
between the allele frequencies were encountered,
although the P value obtained from the tests was much
lower (χ2 = 4.77, P = 0.19; CLUMP T1 = 4.77, P = 0.19).
Table 1
Primer compositions for polymerase chain reactions
Primer name Sequence (5′–3′)
GSTZ1-1F TGACCACCCAGAAGTGTTAG
GSTZ-1R AGTCCACAAGACACAGGTTC
GSTZ1-124G TTCTTACCTGTTGGCCCGCc
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
r
e
s
e
a
r
c
h
 
a
r
t
i
c
l
e
Discussion
GSTZ1 is a member of the GST superfamily of enzymes. A
polymorphic variant of the gene was discovered by Black-
burn et al. in 1999 [8], and the present study investigated
the role of this gene variant in sporadic breast cancer. The
results indicate that there is no evidence of a significant
relationship between any GSTZ1 allele or allele combina-
tion and the development of sporadic breast cancer within
the tested population. It is possible, however, that other
factors such as exposure to certain carcinogens or
lifestyle may influence this result. GSTZ1 may also interact
with other detoxifying enzymes and, to accurately assess
its role, analysis of these additional enzymes should be
taken into account in further studies. It is also a possibility
that the GSTZ1 gene is not expressed, or is only poorly
expressed, in breast tissue because GST enzymes are dif-
ferentially expressed in various tissues [12]. Additional
studies that take other risk factors into account, as well as
matching tumour types, may shed additional light on the
role of GSTZ1 in sporadic breast cancer.
Conclusion
The results of this preliminary study indicate that the
GSTZ1 gene does not appear to play a role in the devel-
opment of sporadic breast cancer. This extends to both
allele and genotype frequencies. The lack of association
with breast cancer indicated in the present study does
not, however, preclude a role in other cancers. Neither do
the results invalidate further studies on GSTZ1 taking dif-
ferent factors such as gene expression or clinical factors
(such as menopausal status) into account.
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Table 2
GSTZ1 genotype frequencies in affected and control populations
Genotype frequencies
Group N (alleles) AA BB CC DD AB AC AD BC BD CD
Affected 206 1 5 45 2 3 7 6 31 0 3
% 0.97 4.85 43.69 1.94 2.91 6.8 5.83 30.1 0 2.91
Control 206 5 10 39 1 5 8 5 27 2 1
% 4.85 9.71 37.86 0.97 4.85 7.77 4.85 26.21 1.94 0.97
CLUMP T1 = 9.02; P = 0.45.
Table 3
GSTZ1 allele frequencies in affected and control populations
Allele frequencies
Group N (alleles) A B C D
Affected 206 18 44 131 13
% 8.74 21.36 63.59 6.31
Control 206 28 54 114 10
% 13.59 26.21 55.34 4.85
Chi-square = 4.77, P = 0.19; CLUMP T1 = 4.77, P = 0.19.